selected publications
- First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis. HemaSphere. 2024 Academic Article GET IT
- An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL. Blood advances. 2024 Academic Article GET IT
- Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study. Blood advances. 2024 Academic Article GET IT
-
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Cancer research.
2024
Academic Article
GET IT
Times cited: 5 - Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
- Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. The Journal of clinical investigation. 2023 Academic Article GET IT
- Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib. 2023 GET IT
- Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical lymphoma, myeloma & leukemia. 2023 Academic Article GET IT
- Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia. 2023 GET IT
- The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy. Haematologica. 2023 Academic Article GET IT
-
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022
Academic Article
GET IT
Times cited: 1 - The clinical importance of prognostic markers in CLL. Clinical advances in hematology & oncology : H&O. 2022 Article GET IT
-
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Blood advances.
2022
Academic Article
GET IT
Times cited: 29 - The future role of bispecific antibodies in lymphoma. Clinical advances in hematology & oncology : H&O. 2022 Article GET IT
-
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood.
2022
Academic Article
GET IT
Times cited: 52 -
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
The Lancet. Haematology.
2022
Academic Article
GET IT
Times cited: 56 -
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
Haematologica.
2022
Academic Article
GET IT
Times cited: 23 -
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Blood advances.
2021
Academic Article
GET IT
Times cited: 19 -
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
British journal of haematology.
2021
Academic Article
GET IT
Times cited: 41 -
Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021
Academic Article
GET IT
Times cited: 61 -
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Blood.
2021
Letter
GET IT
Times cited: 55 -
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021
Academic Article
GET IT
Times cited: 139 -
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
American journal of hematology.
2021
Academic Article
GET IT
Times cited: 1 -
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Haematologica.
2021
Academic Article
GET IT
Times cited: 66 -
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
Blood.
2021
Academic Article
GET IT
Times cited: 59 -
Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
Blood.
2021
Academic Article
GET IT
Times cited: 1 -
Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
American journal of hematology.
2021
Letter
GET IT
Times cited: 3 -
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.
Haematologica.
2021
Letter
GET IT
Times cited: 10 -
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cancer medicine.
2020
Academic Article
GET IT
Times cited: 13 -
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood.
2020
Academic Article
GET IT
Times cited: 242 - The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. Blood and lymphatic cancer : targets and therapy. 2020 Academic Article GET IT
-
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Comment
GET IT
Times cited: 91 -
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
British journal of haematology.
2019
Academic Article
GET IT
Times cited: 23 -
Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
2019
Academic Article
GET IT
Times cited: 4 -
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
Leukemia.
2019
Academic Article
GET IT
Times cited: 18 - Recurrent Gastrointestinal Near-Tetraploid Diffuse Large B-Cell Lymphoma Causing Intussusception and Ileal Ulceration. 2019 GET IT
-
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
Blood advances.
2019
Academic Article
GET IT
Times cited: 25 -
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
Leukemia & lymphoma.
2019
Academic Article
GET IT
Times cited: 11 -
It's not all about the CNS. High dose methotrexate in DLBCL.
Leukemia & lymphoma.
2019
Comment
GET IT
Times cited: 1 -
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia.
Nature.
2019
Academic Article
GET IT
Times cited: 189 -
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL.
Nature communications.
2019
Academic Article
GET IT
Times cited: 59 -
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019
Academic Article
GET IT
Times cited: 63 -
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
American journal of hematology.
2019
Academic Article
GET IT
Times cited: 2 - Current trends in the management of Richter's syndrome. International journal of hematologic oncology. 2019 Review GET IT
-
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
American journal of hematology.
2018
Academic Article
GET IT
Times cited: 58 -
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
British journal of haematology.
2018
Academic Article
GET IT
Times cited: 17 -
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica.
2018
Academic Article
GET IT
Times cited: 136 -
Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.
Cancer research.
2018
Academic Article
GET IT
Times cited: 13 -
Optimal management of the young patient CLL patient.
Best practice & research. Clinical haematology.
2017
Review
GET IT
Times cited: 2 -
Association of Ibrutinib Treatment With Bleeding Complications in Cutaneous Surgery.
2017
GET IT
Times cited: 11 -
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.
Haematologica.
2017
Academic Article
GET IT
Times cited: 32 -
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
Leukemia & lymphoma.
2017
Academic Article
GET IT
Times cited: 11 -
Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.
Leukemia.
2016
Academic Article
GET IT
Times cited: 31 -
Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.
2014
GET IT
Times cited: 2 -
Concise review: Leukemia stem cells in personalized medicine.
Stem cells (Dayton, Ohio).
2014
Review
GET IT
Times cited: 47